Clinical trial
Phase 3 Study of the Efficacy and Safety of Unfractionated Heparin in Patients With Severe Sepsis/Septic Shock With Suspected DIC
NCT02654561 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Study of the Efficacy and Safety of Unfractionated Heparin in Patients With Severe Sepsis/Septic Shock With Suspected DIC
- Lead sponsor
- China Medical University, China
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- April 12, 2018
- Completion date
- June 30, 2025
- Enrollment
- 600 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.